$PMCB
PharmaCyte Biotech, Inc. Stock $pmcb

$pmcb Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-K Financial Statement

#000115707513000010 Filed on July 29, 2013

Income Statement

Concept	2013 Q2	2013	2012 Q2
Revenue	$0.00	$12.16K	$10.00K
YoY Change	-100.0%	-81.73%	-80.0%
Cost Of Revenue	$0.00	$9.620K	$0.00
YoY Change		-50.37%
Gross Profit	$0.00	$2.540K	$10.00K
YoY Change	-100.0%	-94.62%	-80.0%
Gross Profit Margin		20.89%	100.0%
Selling, General & Admin	$460.0K	$723.7K	$490.0K
YoY Change	-6.12%	69.35%	75.0%
% of Gross Profit		28491.5%	4900.0%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
% of Gross Profit		0.0%	0.0%
Operating Expenses	$460.0K	$1.687M	$490.0K
YoY Change	-6.12%	-15.5%	75.0%
Operating Profit	-$460.0K	-$1.684M	-$480.0K
YoY Change	-4.17%	-13.59%	108.7%
Interest Expense	-$40.00K	$112.7K	-$140.0K
YoY Change	-71.43%	-51.03%	366.67%
% of Operating Profit
Other Income/Expense, Net	$0.00	$86.26K	$0.00
YoY Change		72.97%	-100.0%
Pretax Income	-$330.0K	-$1.600M	-$500.0K
YoY Change	-34.0%	-15.79%	-44.44%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$330.0K	-$1.598M	-$500.0K
YoY Change	-34.0%	-15.86%	-44.44%
Net Earnings / Revenue		-13142.29%	-5000.0%
Basic Earnings Per Share		$0.00
Diluted Earnings Per Share	-$710.00	-$3.629K	-$1.214K
COMMON SHARES
Basic Shares Outstanding		441.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2013	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$200.0K	$200.0K	$20.00K
YoY Change	900.0%	900.0%	-66.67%
Cash & Equivalents	$199.3K		$15.72K
Short-Term Investments
Other Short-Term Assets	$1.650M	$1.650M	$1.030M
YoY Change	60.19%	60.19%	3333.33%
Inventory	$0.00	$0.00	$6.846K
Prepaid Expenses
Receivables		$0.00	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$1.848M	$1.850M	$1.059M
YoY Change	74.56%	74.53%	958.73%
LONG-TERM ASSETS
Property, Plant & Equipment		$0.00	$0.00
YoY Change			-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00
YoY Change
Other Assets	$0.00	$1.030M	$1.030M
YoY Change	-100.0%	0.0%	0.0%
Total Long-Term Assets	$1.029M	$1.030M	$1.029M
YoY Change	0.0%	0.0%	-9.76%
TOTAL ASSETS
Total Short-Term Assets	$1.848M	$1.850M	$1.059M
Total Long-Term Assets	$1.029M	$1.030M	$1.029M
Total Assets	$2.877M	$2.880M	$2.088M
YoY Change	37.82%	37.8%	68.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$352.0K	$770.0K	$730.1K
YoY Change	-51.79%	-29.36%	2.83%
Accrued Expenses	$12.30K	$60.00K	$407.5K
YoY Change	-96.98%	-85.71%	50.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$420.0K	$420.0K	$2.090M
YoY Change	-79.9%	-79.9%	-11.81%
Total Short-Term Liabilities	$3.798M	$3.800M	$3.787M
YoY Change	0.29%	0.26%	11.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.798M	$3.800M	$3.787M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.798M	$3.800M	$3.787M
YoY Change	0.29%	0.26%	11.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.45M		-$39.85M
YoY Change	4.01%
Common Stock	$48.21K		$41.63K
YoY Change	15.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.501M	-$920.0K	-$2.280M
YoY Change
Total Liabilities & Shareholders Equity	$2.877M	$2.880M	$2.088M
YoY Change	37.82%	37.8%	68.35%

Cashflow Statement

Concept	2013 Q2	2013	2012 Q2
OPERATING ACTIVITIES
Net Income	-$330.0K	-$1.598M	-$500.0K
YoY Change	-34.0%	-15.86%	-44.44%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Operating Activities	-$140.0K	-$390.4K	-$50.00K
YoY Change	180.0%	50.58%	-66.67%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$170.0K	-$650.0K	-$190.0K
YoY Change	-10.53%	-25.29%
Cash From Investing Activities	-$170.0K	-$646.8K	-$190.0K
YoY Change	-10.53%	-25.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.146M
YoY Change		5357.14%
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	470.0K	$1.221M	220.0K
YoY Change	113.64%	12.04%	15.79%
NET CHANGE
Cash From Operating Activities	-140.0K	-$390.4K	-50.00K
Cash From Investing Activities	-170.0K	-$646.8K	-190.0K
Cash From Financing Activities	470.0K	$1.221M	220.0K
Net Change In Cash	160.0K	$183.6K	-20.00K
YoY Change	-900.0%	-542.6%	-150.0%
FREE CASH FLOW
Cash From Operating Activities	-$140.0K	-$390.4K	-$50.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11461	USD
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	52259	USD
CY2012Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	730068	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	351996	USD
CY2013Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet		USD
CY2012Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	2581	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12300	USD
CY2012Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	407463	USD
CY2012Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	37526524	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39896440	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1160878	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	678707	USD
CY2012	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-10798	USD
CY2012Q2	us-gaap	Business Acquisition Purchase Price Allocation Current Assets Prepaid Expense And Other Assets BusinessAcquisitionPurchasePriceAllocationCurrentAssetsPrepaidExpenseAndOtherAssets	874230	USD
CY2012Q2	us-gaap	Cash Cash	15723	USD
CY2013Q2	us-gaap	Cash Cash	199303	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	199303	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15723	USD
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57201	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	183580	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-5695	USD
CY2012Q2	us-gaap	Assets Assets	2087508	USD
CY2013Q2	us-gaap	Assets Assets	2876931	USD
CY2012Q2	us-gaap	Assets Current AssetsCurrent	1058730	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	1848153	USD
CY2012Q2	us-gaap	Assets Held For Sale Other Noncurrent AssetsHeldForSaleOtherNoncurrent	1028778	USD
CY2013Q2	us-gaap	Assets Held For Sale Other Noncurrent AssetsHeldForSaleOtherNoncurrent	1028778	USD
CY2013Q2	us-gaap	Business Acquisition Purchase Price Allocation Current Assets Prepaid Expense And Other Assets BusinessAcquisitionPurchasePriceAllocationCurrentAssetsPrepaidExpenseAndOtherAssets	1520980	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-41478	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	59433600	shares
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1490000000	shares
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1490000000	shares
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	416293195	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	482106348	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	482106348	shares
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	416293195	shares
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	48211	USD
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	41631	USD
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:14px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains the majority of its cash balances with one financial institution in the form of demand deposits.</font></div></div>
CY2013Q2	us-gaap	Contractual Obligation ContractualObligation	400000	USD
CY2011Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	888889	shares
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	19383	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	9620	USD
CY2012Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12200329	USD
CY2013Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12457023	USD
CY2013Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2012Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2012Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35883321	USD
CY2013Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36638304	USD
CY2011Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35372287	USD
CY2012Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	-24659	USD
CY2013Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	-984696	USD
CY2012Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	-1570280	USD
CY2012Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	-6497	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	0	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	0	USD
CY2012Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	-79503	USD
CY2012Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12200329	USD
CY2013Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12457023	USD
CY2013	us-gaap	Depreciation Depreciation	0	USD
CY2012	us-gaap	Depreciation Depreciation	24659	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	24659	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	USD
CY2012Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	185862	USD
CY2013Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	201143	USD
CY2013Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	419583	USD
CY2012Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	360108	USD
CY2012Q2	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent		USD
CY2013Q2	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent		USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.34
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.34
CY2012	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-79503	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-39000	USD
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	617271	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	416171	USD
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	us-gaap	Gross Profit GrossProfit	2540	USD
CY2012	us-gaap	Gross Profit GrossProfit	47175	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	173825	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	97708	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6762	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2581	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	153957	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	192654	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-11860	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6846	USD
CY2012	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	132826	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-62667	USD
CY2013	us-gaap	Interest Expense InterestExpense	112662	USD
CY2012	us-gaap	Interest Expense InterestExpense	230073	USD
CY2013	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	41754	USD
CY2012	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	11173	USD
CY2012	us-gaap	Interest Paid InterestPaid	0	USD
CY2012Q2	us-gaap	Inventory Net InventoryNet	6846	USD
CY2013Q2	us-gaap	Inventory Net InventoryNet	0	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	56763	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	41823	USD
CY2013Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2341106	USD
CY2013	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2590	USD
CY2012	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2012	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	874230	USD
CY2013	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	646750	USD
CY2011Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3500	shares
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1160880	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6497	USD
CY2013Q2	us-gaap	Liabilities Liabilities	3798387	USD
CY2012Q2	us-gaap	Liabilities Liabilities	3787358	USD
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2087508	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2876931	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3798387	USD
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3787358	USD
CY2012Q2	us-gaap	Loans Payable Current LoansPayableCurrent	2092396	USD
CY2013Q2	us-gaap	Loans Payable Current LoansPayableCurrent	420000	USD
CY2013Q2	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.08
CY2013Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	20000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1220756	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1089541	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-871730	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-646750	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-390426	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-259289	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-1598102	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-1899312	USD
CY2012	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	81000	USD
CY2013	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	0	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	49870	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	86259	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	1996357	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	1686901	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-1949182	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-1684361	USD
CY2012Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1899312	USD
CY2013Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1598102	USD
CY2012Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	580000	USD
CY2012Q2	us-gaap	Preferred Stock Value PreferredStockValue	580000	USD
CY2013	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	50000
CY2012Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	159350	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	127870	USD
CY2013	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:14px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain items in the prior year financial statements have been reclassified for comparative purposes to conform to the presentation in the current period’s presentation. These reclassifications have no effect on the previously reported income (loss).</font></div></div>
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1146000	USD
CY2013	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1136000	USD
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	660000	USD
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2013	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	149756	USD
CY2012	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	533546	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2012	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2500	USD
CY2013	us-gaap	Professional Fees ProfessionalFees	284510	USD
CY2012	us-gaap	Professional Fees ProfessionalFees	327158	USD
CY2013	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2012	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	100000	USD
CY2012	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	25005	USD
CY2013	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	75000	USD
CY2012Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39848005	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41446107	USD
CY2013	us-gaap	Revenues Revenues	12160	USD
CY2012	us-gaap	Revenues Revenues	66558	USD
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	66558	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	12160	USD
CY2012	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	409400	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	653696	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	-2279850	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-1501456	USD
CY2011Q2	us-gaap	Stockholders Equity StockholdersEquity	-2729293	USD
CY2013Q2	nvlx	Deferred Tax Assets Loss On Debt Conversion DeferredTaxAssetsLossOnDebtConversion	-39000	USD
CY2012Q2	nvlx	Deferred Tax Assets Shares Issued For Interest Expense DeferredTaxAssetsSharesIssuedForInterestExpense	-101750	USD
CY2013	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	106413	USD
CY2012	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11150	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1570280	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	984696	USD
CY2012	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1025000	shares
CY2012	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	8550000	shares
CY2013	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	100000000	shares
CY2012	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	23575000	shares
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	55725	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	331000	USD
CY2012	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	409400	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000	USD
CY2013	us-gaap	Subsidiary Or Equity Method Investee Cumulative Percentage Ownership After All Transactions SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions	0.145
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:14px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	256694	USD
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	440954850	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	374763486	shares
CY2011Q2	nvlx	Average Closing Bid Price AverageClosingBidPrice	0.09
CY2013	nvlx	Classof Warrantor Right Total Funds Expected To Be Raised ClassofWarrantorRightTotalFundsExpectedToBeRaised	7429200	USD
CY2013	nvlx	Common Stock Issued For Debt CommonStockIssuedForDebt	143596	USD
CY2012	nvlx	Common Stock Issued For Debt CommonStockIssuedForDebt	600000	USD
CY2013Q2	nvlx	Deferred Tax Assets Debt Discount Amortization DeferredTaxAssetsDebtDiscountAmortization	5695	USD
CY2012Q2	nvlx	Deferred Tax Assets Debt Discount Amortization DeferredTaxAssetsDebtDiscountAmortization	10798	USD
CY2013Q2	nvlx	Deferred Tax Assets Gain On Forgiveness Of Debt DeferredTaxAssetsGainOnForgivenessOfDebt	277085	USD
CY2012Q2	nvlx	Deferred Tax Assets Gain On Forgiveness Of Debt DeferredTaxAssetsGainOnForgivenessOfDebt	370619	USD
CY2012Q2	nvlx	Deferred Tax Assets Loss On Debt Conversion DeferredTaxAssetsLossOnDebtConversion	0	USD
CY2013Q2	nvlx	Deferred Tax Assets Shares Issued For Interest Expense DeferredTaxAssetsSharesIssuedForInterestExpense	-102203	USD
CY2012	nvlx	Gain On Repayment Of Debt GainOnRepaymentOfDebt	370619	USD
CY2013	nvlx	Gains Losses On Forgiveness Of Debt GainsLossesOnForgivenessOfDebt	277085	USD
CY2012	nvlx	Gains Losses On Forgiveness Of Debt GainsLossesOnForgivenessOfDebt	370619	USD
CY2013	nvlx	Increase In Accrued Interest Related Party IncreaseInAccruedInterestRelatedParty	40798	USD
CY2012	nvlx	Increase In Accrued Interest Related Party IncreaseInAccruedInterestRelatedParty		USD
CY2012	nvlx	Shares Issued For Incentive For Cash Advances Amount SharesIssuedForIncentiveForCashAdvancesAmount	101750	USD
CY2012	nvlx	Shares Issued For Repayment Of Cash Advances Amount SharesIssuedForRepaymentOfCashAdvancesAmount	600000	USD
CY2012	nvlx	Shares Issued For Settlement Of Debt Amount SharesIssuedForSettlementOfDebtAmount	55725	USD
CY2013	nvlx	Shares Issued For Settlement Of Debt Amount SharesIssuedForSettlementOfDebtAmount	143596	USD
CY2013	nvlx	Stock Issued During Period For Interest Expense Amount StockIssuedDuringPeriodForInterestExpenseAmount	102203	USD
CY2012	nvlx	Stock Issued During Period For Interest Expense Amount StockIssuedDuringPeriodForInterestExpenseAmount	101750	USD
CY2013	nvlx	Stock Issued During Period For Private Placement Memo Amount StockIssuedDuringPeriodForPrivatePlacementMemoAmount	1238204	USD
CY2012	nvlx	Stock Issued On Stock Payable Amount StockIssuedOnStockPayableAmount	0	USD
CY2013Q2	nvlx	Working Capital WorkingCapital	-1950234	USD
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-04-30
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001157075
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	509931348	shares
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012Q4	dei	Entity Public Float EntityPublicFloat	6326212	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	NUVILEX, INC.
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No

Files In Submission

Name	View Source	Status
0001157075-13-000010-index-headers.html	Edgar Link	pending
0001157075-13-000010-index.html	Edgar Link	pending
0001157075-13-000010.txt	Edgar Link	pending
0001157075-13-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nvlx-04302013x10k.htm	Edgar Link	pending
nvlx-04302013xex141.htm	Edgar Link	pending
nvlx-04302013xex211.htm	Edgar Link	pending
nvlx-04302013xex311.htm	Edgar Link	pending
nvlx-04302013xex312.htm	Edgar Link	pending
nvlx-04302013xex321.htm	Edgar Link	pending
nvlx-04302013xex322.htm	Edgar Link	pending
nvlx-20130430.xml	Edgar Link	completed
nvlx-20130430.xsd	Edgar Link	pending
nvlx-20130430_cal.xml	Edgar Link	unprocessable
nvlx-20130430_def.xml	Edgar Link	unprocessable
nvlx-20130430_lab.xml	Edgar Link	unprocessable
nvlx-20130430_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PMCB
PharmaCyte Biotech, Inc. Stock $pmcb

2013 Q2 Form 10-K Financial Statement

#000115707513000010 Filed on July 29, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMCB PharmaCyte Biotech, Inc. Stock $pmcb

2013 Q2 Form 10-K Financial Statement

#000115707513000010 Filed on July 29, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMCB
PharmaCyte Biotech, Inc. Stock $pmcb